Positive Recommendation from DSMB for Ph 3 Study of Bria-IMT + CPI in Metastatic Breast Cancer June 2, 2026
First patients dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Ph 1/2a studies in neuroendocrine tumors and solid tumors May 26, 2026
First patient dosed in Spain in Ph 2 HLX43-NSCLC201 trial of HLX43 for the treatment of advanced NSCLC May 26, 2026
First interim unblinding expected in June 2026 following 45 subject enrollment milestone achieved in MIRACLE trial May 21, 2026
First Patient Dosed in ASPENOVA Ph 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer May 12, 2026
First patient dosed in clinical trial of EDV™ (EnGeneIC Dream Vector) therapy in patients with recurrent GBM May 12, 2026
Study initiated to evaluate Pidnarulex (CX-5461) + tislelizumab in pancreatic cancer, colorectal cancer, and melanoma May 12, 2026
DMC recommends halting Ph 3 FLASH2 trial of HyBryt (Synthetic Hypericin) in the treatment of CTCL patients post interim efficacy analysis May 6, 2026
TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors April 28, 2026
